20 results on '"Bernstein D"'
Search Results
2. Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
3. Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC
4. Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
5. All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3+
6. THU-225 - Primary biliary cholangitis (PBC) in the U.S.: clinical characteristics of patients enrolled in TARGET-PBC
7. THU-224 - Primary biliary cholangitis (PBC) in the U.S.: real world effectiveness of obeticholic acid in TARGET-PBC
8. LBP-002 - Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
9. P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study
10. P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials
11. LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
12. LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study
13. P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN
14. SAT-199 - All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3+
15. SAT-138 - Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis
16. 917 PROACTIVE BIRTH-COHORT AND RISK-BASED HEPATITIS C SCREENING: HEP C LINK TO CARE NYC
17. 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
18. 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY
19. [8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE?
20. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.